Menu
GeneBe

IRF4

interferon regulatory factor 4, the group of Interferon regulatory factors

Basic information

Region (hg38): 6:391738-411443

Previous symbols: [ "MUM1" ]

Links

ENSG00000137265NCBI:3662OMIM:601900HGNC:6119Uniprot:Q15306AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Skin/hair/eye pigmentation, variation in, 8ADGeneralThough potentially related to melanoma susceptibility, the clinical relevance of the condition is unclearDermatologic17952075; 18483556; 19710684; 20602913; 24267888

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the IRF4 gene.

  • not provided (204 variants)
  • Inborn genetic diseases (10 variants)
  • not specified (5 variants)
  • IRF4-related condition (2 variants)
  • SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the IRF4 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
72
clinvar
3
clinvar
76
missense
1
clinvar
80
clinvar
2
clinvar
3
clinvar
86
nonsense
1
clinvar
1
start loss
0
frameshift
1
clinvar
1
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
2
clinvar
2
splice region
2
6
1
9
non coding
1
clinvar
10
clinvar
23
clinvar
34
Total 1 0 87 84 29

Variants in IRF4

This is a list of pathogenic ClinVar variants found in the IRF4 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
6-392783-G-A Benign (Nov 12, 2018)1272812
6-392866-A-G Benign (Nov 12, 2018)1278447
6-393154-T-G Likely benign (Aug 17, 2023)2852933
6-393158-C-T Likely benign (May 20, 2021)1555544
6-393159-C-T Likely benign (Aug 03, 2023)2729493
6-393166-G-A Uncertain significance (Nov 10, 2023)2780101
6-393168-G-C Uncertain significance (May 26, 2023)2968043
6-393172-G-A Uncertain significance (Sep 07, 2022)1395491
6-393175-G-A not specified Conflicting classifications of pathogenicity (Jan 25, 2024)1414544
6-393175-G-T Uncertain significance (Aug 15, 2022)1390195
6-393179-C-T Likely benign (Aug 04, 2023)1634528
6-393188-C-G Uncertain significance (Aug 21, 2022)1351821
6-393191-C-T Likely benign (Jan 11, 2024)2790560
6-393193-T-C Uncertain significance (Apr 18, 2022)2127608
6-393205-G-A Uncertain significance (Oct 06, 2023)2969143
6-393205-G-C Uncertain significance (Apr 03, 2023)2896292
6-393218-G-A Likely benign (Oct 05, 2023)1958125
6-393225-C-G Uncertain significance (Sep 29, 2021)1383762
6-393227-C-T Likely benign (Aug 17, 2023)1484917
6-393238-T-G Uncertain significance (Dec 24, 2020)1461971
6-393243-C-G Uncertain significance (Aug 23, 2022)1717885
6-393264-C-T Uncertain significance (Oct 30, 2023)2177075
6-393272-G-A Likely benign (Nov 22, 2023)1532310
6-393281-G-A Likely benign (Feb 24, 2023)2964784
6-393284-CGAG-C Uncertain significance (Jul 09, 2022)1954294

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
IRF4protein_codingprotein_codingENST00000380956 819709
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.8570.1431257300181257480.0000716
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense2.851442780.5180.00001642960
Missense in Polyphen33101.580.324881106
Synonymous0.3091151190.9640.00000813845
Loss of Function3.78424.00.1670.00000130248

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001590.000156
Ashkenazi Jewish0.000.00
East Asian0.0005870.000544
Finnish0.00004680.0000462
European (Non-Finnish)0.00001800.0000176
Middle Eastern0.0005870.000544
South Asian0.00003680.0000327
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transcriptional activator. Binds to the interferon- stimulated response element (ISRE) of the MHC class I promoter. Binds the immunoglobulin lambda light chain enhancer, together with PU.1. Probably plays a role in ISRE-targeted signal transduction mechanisms specific to lymphoid cells. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF4 and activation of genes (By similarity). {ECO:0000250|UniProtKB:Q64287}.;
Disease
DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. {ECO:0000269|PubMed:9326949}. Note=The gene represented in this entry may be involved in disease pathogenesis. A chromosomal aberration involving IRF4 has been found in multiple myeloma. Translocation t(6;14)(p25;q32) with the IgH locus.;
Pathway
Th17 cell differentiation - Homo sapiens (human);White fat cell differentiation;B Cell Receptor Signaling Pathway;Apoptosis;Vitamin D Receptor Pathway;Preimplantation Embryo;Apoptotic Signaling Pathway;Development of pulmonary dendritic cells and macrophage subsets;Prion disease pathway;Interleukin-4 and 13 signaling;White fat cell differentiation;Type II interferon signaling (IFNG);T-Cell antigen Receptor (TCR) Signaling Pathway;the information processing pathway at the ifn beta enhancer;Cytokine Signaling in Immune system;Immune System;Interferon gamma signaling;Interferon alpha/beta signaling;Calcineurin-regulated NFAT-dependent transcription in lymphocytes;Interferon Signaling;IL4-mediated signaling events (Consensus)

Recessive Scores

pRec
0.304

Intolerance Scores

loftool
0.136
rvis_EVS
-0.6
rvis_percentile_EVS
17.91

Haploinsufficiency Scores

pHI
0.268
hipred
Y
hipred_score
0.825
ghis
0.621

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
1.00

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Irf4
Phenotype
growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype; hematopoietic system phenotype; neoplasm; immune system phenotype;

Zebrafish Information Network

Gene name
irf4a
Affected structure
thymus
Phenotype tag
abnormal
Phenotype quality
decreased amount

Gene ontology

Biological process
peptidyl-lysine methylation;cytokine-mediated signaling pathway;negative regulation of toll-like receptor signaling pathway;T cell activation;defense response to protozoan;myeloid dendritic cell differentiation;positive regulation of DNA binding;histone H3 acetylation;histone H4 acetylation;positive regulation of interleukin-10 biosynthetic process;positive regulation of interleukin-2 biosynthetic process;positive regulation of interleukin-13 biosynthetic process;positive regulation of interleukin-4 biosynthetic process;regulation of T-helper cell differentiation;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;interferon-gamma-mediated signaling pathway;type I interferon signaling pathway;T-helper 17 cell lineage commitment;positive regulation of cold-induced thermogenesis
Cellular component
nuclear nucleosome;nucleus;nucleoplasm;cytosol;membrane
Molecular function
RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA-binding transcription factor activity;protein binding;transcription factor binding;protein-lysine N-methyltransferase activity;sequence-specific DNA binding